<SEC-DOCUMENT>0001564590-20-051424.txt : 20201105
<SEC-HEADER>0001564590-20-051424.hdr.sgml : 20201105
<ACCEPTANCE-DATETIME>20201105165135
ACCESSION NUMBER:		0001564590-20-051424
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20201104
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201105
DATE AS OF CHANGE:		20201105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0103

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		201291287

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>staa-8k_20201104.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-11-05T21:29:24.6366785+00:00 -->
<!-- Version            : 5.0.1.513 -->
<!-- Package ID         : 19f603d00a14401e81da3bc6ac88d593 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:staa="http://www.staar.com/20201104" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
staa-8k_20201104.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000718937_20201104_20201104">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0000718937_20201104_20201104">0000718937</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="staa-20201104.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000718937_20201104_20201104">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000718937</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-04</xbrli:startDate>
					<xbrli:endDate>2020-11-04</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;margin-left:37.49%;margin-right:34.51%;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U<span style="letter-spacing:-0.05pt;">N</span>IT<span style="letter-spacing:-0.05pt;">E</span>D S<span style="letter-spacing:0.05pt;">T</span>A<span style="letter-spacing:0.05pt;">T</span>ES</p>
<p style="text-align:center;margin-bottom:0pt;line-height:20pt;margin-top:0pt;margin-left:14.71%;margin-right:11.75%;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S<span style="letter-spacing:-0.05pt;">E</span>C<span style="letter-spacing:-0.05pt;">U</span><span style="letter-spacing:0.05pt;">R</span>IT<span style="letter-spacing:-0.1pt;">I</span><span style="letter-spacing:0.1pt;">E</span>S A<span style="letter-spacing:-0.05pt;">N</span>D E<span style="letter-spacing:0.2pt;">X</span>CHA<span style="letter-spacing:-0.05pt;">N</span>GE<span style="letter-spacing:0.05pt;"> </span>CO<span style="letter-spacing:-0.05pt;">M</span>MISSION</p>
<p style="text-align:center;margin-bottom:0pt;line-height:13pt;margin-top:0pt;margin-left:37.46%;margin-right:35.07%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WAS<span style="letter-spacing:0.05pt;">H</span>IN<span style="letter-spacing:-0.1pt;">G</span>TON, DC<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.1pt;">2</span>0549</p>
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40.3%;margin-right:40.3%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000718937_20201104_20201104">8-K</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40.3%;margin-right:40.3%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:33.24%;margin-right:30.41%;text-indent:0.01%;font-weight:bold;font-size:12pt;font-family:Times New Roman;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">P<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:0.05pt;">u</span>a<span style="letter-spacing:0.05pt;">n</span>t <span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:0.05pt;">S</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>tion<span style="letter-spacing:0.1pt;"> </span>13 or<span style="letter-spacing:-0.05pt;"> </span>15(d) of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span>e <span style="letter-spacing:0.05pt;">S</span><span style="letter-spacing:-0.05pt;">ec</span><span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>ities Excha<span style="letter-spacing:0.05pt;">n</span>ge<span style="letter-spacing:-0.05pt;"> </span>A<span style="letter-spacing:0.05pt;">c</span>t of<span style="letter-spacing:0.05pt;"> </span>1934</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;line-height:13pt;margin-top:0pt;margin-left:17.08%;margin-right:14.74%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Da<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">re</span><span style="letter-spacing:0.05pt;">p</span>o<span style="letter-spacing:-0.05pt;">r</span>t<span style="letter-spacing:0.05pt;"> </span>(<span style="letter-spacing:-0.05pt;">D</span>a<span style="letter-spacing:0.05pt;">t</span>e<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>a<span style="letter-spacing:-0.05pt;">r</span>l<span style="letter-spacing:0.05pt;">i</span><span style="letter-spacing:-0.05pt;">e</span>st <span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.1pt;">v</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span>t <span style="letter-spacing:-0.1pt;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">p</span>o<span style="letter-spacing:0.05pt;">r</span>t<span style="letter-spacing:-0.1pt;">e</span><span style="letter-spacing:0.05pt;">d)</span>: <span style="letter-spacing:-0.7pt;"> </span><ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000718937_20201104_20201104" format="ixt:datemonthdayyearen">November 4, 2020</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:7pt;text-indent:0%;font-size:7.5pt;">&#160;</p>

<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;line-height:11pt;margin-left:30.41%;margin-right:28.17%;text-indent:0%;font-weight:bold;color:#000000;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0000718937_20201104_20201104">STAAR Surgical Co</ix:nonNumeric>mpany<span style="letter-spacing:0.05pt;color:#000000;"> </span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;line-height:11pt;margin-left:30.35%;margin-right:28.17%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;font-style:normal;text-transform:none;font-variant: normal;">(<span style="letter-spacing:-0.05pt;">Ex</span>act<span style="letter-spacing:-0.25pt;"> </span>N<span style="letter-spacing:0.2pt;">a</span><span style="letter-spacing:-0.15pt;">m</span>e<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Re<span style="letter-spacing:0.1pt;">g</span>i<span style="letter-spacing:-0.05pt;">s</span>trant<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.1pt;"> </span>S<span style="letter-spacing:-0.05pt;">p</span>ecified<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.1pt;">i</span>n<span style="letter-spacing:-0.1pt;"> </span>Charter)</p>
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.72%;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000718937_20201104_20201104" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0000718937_20201104_20201104">0-11634</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000718937_20201104_20201104">95-3797439</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr style="height:12pt;">
<td valign="bottom" style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0000718937_20201104_20201104">25651 Atlantic Ocean Drive</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityAddressCityOrTown" contextRef="C_0000718937_20201104_20201104">Lake Forest</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressStateOrProvince" contextRef="C_0000718937_20201104_20201104" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityAddressPostalZipCode" contextRef="C_0000718937_20201104_20201104">92630</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: <span style="text-decoration:underline;font-family:Times New Roman;"><ix:nonNumeric id="F_000013" name="dei:CityAreaCode" contextRef="C_0000718937_20201104_20201104">626</ix:nonNumeric></span>-<ix:nonNumeric id="F_000014" name="dei:LocalPhoneNumber" contextRef="C_0000718937_20201104_20201104">303-7902</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable </p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report) </p>
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0.93%;margin-right:1.87%;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Che<span style="letter-spacing:0.15pt;">c</span>k<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.1pt;">t</span>he a<span style="letter-spacing:0.05pt;">ppropr</span>iate<span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:0.05pt;">bo</span>x<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e<span style="letter-spacing:-0.1pt;">l</span><span style="letter-spacing:0.15pt;">o</span>w<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">i</span>f<span style="letter-spacing:0.1pt;"> </span>the F<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:0.15pt;">r</span>m<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">8</span><span style="letter-spacing:-0.1pt;">-</span>K <span style="letter-spacing:-0.1pt;">f</span>il<span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:0.05pt;">n</span>ten<span style="letter-spacing:0.05pt;">d</span>ed<span style="letter-spacing:-0.25pt;"> </span>to s<span style="letter-spacing:0.1pt;">i</span>mult<span style="letter-spacing:0.1pt;">a</span>ne<span style="letter-spacing:0.05pt;">o</span>u<span style="letter-spacing:0.1pt;">sl</span>y<span style="letter-spacing:-0.65pt;"> </span>sati<span style="letter-spacing:0.1pt;">s</span><span style="letter-spacing:0.05pt;">f</span>y<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.1pt;">t</span>he<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.1pt;">f</span>il<span style="letter-spacing:0.1pt;">i</span>ng<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">ob</span>l<span style="letter-spacing:0.1pt;">i</span>gati<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">o</span>f<span style="letter-spacing:-0.15pt;"> </span>the <span style="letter-spacing:0.15pt;">r</span>egistr<span style="letter-spacing:0.15pt;">a</span>nt un<span style="letter-spacing:0.05pt;">d</span>er<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>y<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">t</span>he <span style="letter-spacing:-0.1pt;">f</span><span style="letter-spacing:0.05pt;">o</span>ll<span style="letter-spacing:0.15pt;">o</span><span style="letter-spacing:-0.1pt;">w</span><span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.05pt;">pro</span>visi<span style="letter-spacing:0.15pt;">o</span>ns<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.25pt;">(</span><span style="font-style:italic;">s</span><span style="font-style:italic;">ee</span><span style="font-style:italic;"> </span>G<span style="letter-spacing:0.15pt;">e</span>ne<span style="letter-spacing:0.05pt;">r</span>al<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">I</span>n<span style="letter-spacing:0.1pt;">s</span>tructi<span style="letter-spacing:0.15pt;">o</span>n<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">A</span>.<span style="letter-spacing:0.05pt;">2</span>.<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">b</span>el<span style="letter-spacing:0.2pt;">o</span><span style="letter-spacing:-0.25pt;">w</span><span style="letter-spacing:0.05pt;">)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:right;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:96%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:WrittenCommunications" contextRef="C_0000718937_20201104_20201104" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:SolicitingMaterial" contextRef="C_0000718937_20201104_20201104" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:PreCommencementTenderOffer" contextRef="C_0000718937_20201104_20201104" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000718937_20201104_20201104" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:96.04%;">
<tr>
<td style="width:32.01%;"></td>
<td style="width:32.01%;"></td>
<td style="width:32.01%;"></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:Security12bTitle" contextRef="C_0000718937_20201104_20201104">Common</ix:nonNumeric></p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:TradingSymbol" contextRef="C_0000718937_20201104_20201104">STAA</ix:nonNumeric></p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:SecurityExchangeName" contextRef="C_0000718937_20201104_20201104">NASDAQ</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;line-height:11pt;margin-top:0pt;margin-left:0.93%;margin-right:0.56%;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="letter-spacing:-0.05pt;">n</span>dicate<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">b</span>y<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:0.15pt;">c</span>k<span style="letter-spacing:-0.2pt;"> m</span>a<span style="letter-spacing:0.15pt;">r</span>k<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">w</span><span style="letter-spacing:-0.05pt;">h</span><span style="letter-spacing:0.15pt;">e</span>ther<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:-0.05pt;">g</span>i<span style="letter-spacing:-0.05pt;">s</span>tr<span style="letter-spacing:0.15pt;">a</span><span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.4pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.15pt;">a</span>n<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">e</span><span style="letter-spacing:-0.05pt;">m</span>er<span style="letter-spacing:-0.05pt;">g</span><span style="letter-spacing:0.1pt;">i</span>ng<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">g</span>r<span style="letter-spacing:0.15pt;">o</span><span style="letter-spacing:-0.1pt;">w</span><span style="letter-spacing:0.1pt;">t</span>h<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:0.2pt;">o</span><span style="letter-spacing:-0.2pt;">m</span>pany<span style="letter-spacing:-0.4pt;"> </span>as<span style="letter-spacing:-0.1pt;"> </span>defi<span style="letter-spacing:-0.05pt;">n</span>ed<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>R<span style="letter-spacing:-0.05pt;">u</span>le<span style="letter-spacing:-0.2pt;"> </span>405<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>Se<span style="letter-spacing:0.15pt;">c</span><span style="letter-spacing:-0.05pt;">u</span>rities<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">A</span>ct<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">o</span>f<span style="letter-spacing:-0.15pt;"> </span>1<span style="letter-spacing:-1.8pt;"> </span>933 (17<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">C</span>FR<span style="letter-spacing:-0.25pt;"> </span>&#167;230<span style="letter-spacing:-0.1pt;">.</span>405)<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> Ru</span>le<span style="letter-spacing:-0.2pt;"> </span>1<span style="letter-spacing:-0.05pt;">2</span><span style="letter-spacing:0.25pt;">b</span><span style="letter-spacing:-0.1pt;">-</span>2<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>Se<span style="letter-spacing:0.15pt;">c</span><span style="letter-spacing:-0.05pt;">u</span>rities<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">E</span><span style="letter-spacing:-0.05pt;">x</span><span style="letter-spacing:0.15pt;">c</span>han<span style="letter-spacing:-0.05pt;">g</span>e<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">A</span>ct<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>1934<span style="letter-spacing:-0.15pt;"> </span>(17<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">C</span>FR<span style="letter-spacing:-0.25pt;"> </span>&#167;240<span style="letter-spacing:-0.1pt;">.</span>1<span style="letter-spacing:-0.05pt;">2</span><span style="letter-spacing:0.3pt;">b</span><span style="letter-spacing:-0.1pt;">-</span>2).</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0.94%;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E<span style="letter-spacing:-0.2pt;">m</span>e<span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">g</span><span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">g</span><span style="letter-spacing:0.05pt;">r</span>o<span style="letter-spacing:-0.1pt;">w</span><span style="letter-spacing:0.1pt;">t</span>h<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:0.2pt;">o</span><span style="letter-spacing:-0.2pt;">m</span><span style="letter-spacing:0.05pt;">p</span>a<span style="letter-spacing:0.05pt;">n</span>y<span style="letter-spacing:1.3pt;"> </span><span style="font-family:Segoe UI Symbol;letter-spacing:1.3pt;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000718937_20201104_20201104" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:5pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0.93%;margin-right:2.43%;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">e</span><span style="letter-spacing:-0.05pt;">m</span>er<span style="letter-spacing:-0.05pt;">g</span><span style="letter-spacing:0.1pt;">i</span>ng<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">g</span>r<span style="letter-spacing:0.15pt;">o</span><span style="letter-spacing:-0.1pt;">w</span>th<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:0.2pt;">o</span><span style="letter-spacing:-0.2pt;">m</span>p<span style="letter-spacing:0.15pt;">a</span>n<span style="letter-spacing:-0.2pt;">y</span>,<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:-0.05pt;">n</span>dicate<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">b</span>y<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:0.15pt;">c</span>k<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">m</span>ark<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.1pt;">i</span>f<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">t</span><span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:-0.05pt;">g</span>istra<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">h</span>as<span style="letter-spacing:-0.15pt;"> </span>elected<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">n</span>ot<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:0.1pt;"> </span><span style="letter-spacing:-0.05pt;">us</span>e<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">t</span><span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>e<span style="letter-spacing:-0.05pt;">x</span>t<span style="letter-spacing:0.1pt;">e</span><span style="letter-spacing:-0.05pt;">n</span>ded<span style="letter-spacing:-0.25pt;"> </span>tra<span style="letter-spacing:-0.05pt;">ns</span>i<span style="letter-spacing:0.1pt;">t</span>ion<span style="letter-spacing:-0.45pt;"> </span>period<span style="letter-spacing:0.5pt;"> </span><span style="letter-spacing:-0.1pt;">f</span>or co<span style="letter-spacing:-0.2pt;">m</span>p<span style="letter-spacing:0.1pt;">l</span><span style="letter-spacing:-0.05pt;">y</span><span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:-0.05pt;">n</span>g<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">w</span><span style="letter-spacing:0.1pt;">i</span>th<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">a</span>ny<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">n</span><span style="letter-spacing:0.15pt;">e</span>w<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:-0.05pt;">v</span>i<span style="letter-spacing:-0.05pt;">s</span>ed<span style="letter-spacing:-0.1pt;"> f</span>i<span style="letter-spacing:-0.05pt;">n</span><span style="letter-spacing:0.15pt;">a</span><span style="letter-spacing:-0.05pt;">n</span>cial<span style="letter-spacing:-0.3pt;"> </span>accou<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:0.1pt;">i</span>ng<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.05pt;">s</span>t<span style="letter-spacing:0.1pt;">a</span><span style="letter-spacing:-0.05pt;">n</span>da<span style="letter-spacing:0.4pt;">r</span>ds<span style="letter-spacing:-0.4pt;"> </span>pro<span style="letter-spacing:-0.05pt;">v</span>ided<span style="letter-spacing:-0.25pt;"> </span>p<span style="letter-spacing:-0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;">su</span>a<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.1pt;">S</span>ection<span style="letter-spacing:-0.35pt;"> </span>13(a)<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>E<span style="letter-spacing:-0.05pt;">x</span>c<span style="letter-spacing:-0.05pt;">h</span><span style="letter-spacing:0.15pt;">a</span>n<span style="letter-spacing:-0.05pt;">g</span>e<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">A</span>ct.<span style="letter-spacing:1.8pt;"> </span><span style="font-family:Segoe UI Symbol;letter-spacing:1.8pt;">&#9744;</span></p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0.93%;margin-right:2.43%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0.93%;margin-right:2.43%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:MS Mincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 7.01 Regulation FD Disclosure.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 4, 2020, the Company held a conference call to discuss the financial results for the quarter ended October 2, 2020.&#160;&#160;A transcript of the conference call is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report, and Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01 Financial Statements and Exhibits</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:568.75pt;;">
<tr>
<td style="width:85.3pt;"></td>
<td style="width:11.35pt;"></td>
<td style="width:2.35pt;"></td>
<td style="width:469.75pt;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Exhibit No.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Description</span></p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="staa-ex991_15.htm"><span style="text-decoration:underline;">Transcript of conference call of the Company held on November 4, 2020</span></a><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.72%;"><span style="margin-left:36pt;"></span>&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:568.5pt;;">
<tr>
<td style="width:85.25pt;"></td>
<td style="width:11.35pt;"></td>
<td style="width:471.9pt;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:568.8pt;;">
<tr>
<td style="width:85.3pt;"></td>
<td style="width:18.2pt;"></td>
<td style="width:465.3pt;"></td>
</tr>
<tr>
<td colspan="3" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STAAR Surgical Company&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 5, 2020</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">/s/ Caren Mason</span></p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Caren Mason</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>staa-ex991_15.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
staa-ex991_15.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">STAAR Surgical Q3 2020 Earnings Call Transcript</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 4, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">CORPORATE PARTICIPANTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Caren Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patrick F. Williams, Chief Financial Officer, STAAR Surgical</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brian Moore, Vice President-Investor, Media Relations and Corporate Development, STAAR Surgical</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">OTHER PARTICIPANTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthony Petrone, Analyst, Jefferies LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chris Cooley, Analyst, Stephens, Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Zimmerman, Analyst, BTIG LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andrew Brackmann, Analyst, William Blair &amp; Co. LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bruce D. Jackson, Analyst, The Benchmark Co. LLC</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><br />MANAGEMENT DISCUSSION SECTION</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Operator</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Good day, ladies and gentlemen. Thank you for standing by. Welcome to the STAAR Surgical Third Quarter 2020 Financial Results Conference Call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the call will be open for questions. [Operator Instructions] This call is being recorded today Wednesday November 4, 2020. At this time, I would like to turn the conference over to Mr. Brian Moore, Vice President, Investor, Media Relations and Corporate Development for STAAR Surgical.</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Brian Moore, Vice President-Investor, Media Relations and Corporate Development, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Staci, and good afternoon everyone. Thank you for joining us on the STAAR Surgical conference call this afternoon to discuss the company's financial results for the third quarter ended October 2, 2020. On the call today are Caren Mason, President and Chief Executive Officer and Patrick Williams, Chief Financial Officer. The press release of our third quarter results was issued just after 4:00 PM Eastern Time and is now available on STAAR's website at <font style="text-decoration:underline;">www.staar.com</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before we begin, let me quickly remind you that during the course of this conference call, the company will make forward-looking statements. We caution you that any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the company's projections, expectations, plans, beliefs, and prospects.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These statements are based on judgment and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risks and uncertainties associated with the forward-looking statements made in this conference call and webcast are described in the Safe Harbor statement in today's press release, as well as STAAR's public periodic filings with the SEC. Except as required by law, STAAR assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes, and does not intend to do so. </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, to supplement the GAAP numbers, we have provided non-GAAP adjusted net income and adjusted earnings per share and sales in constant currency. We believe that these non-GAAP numbers provide meaningful supplemental information and are helpful in assessing our historical and future performance. A table reconciling the GAAP information to the non-GAAP information is included in today's press release. Following our prepared remarks, we will open the line to questions from publishing analysts. We ask analysts limit </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">themselves </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to two initial questions, then re-queue with any follow-ups. We thank everyone in advance for their cooperation with this process.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And with that, I would now like to turn the call over to Caren Mason, President and CEO of STAAR</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason - President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Brian. Good afternoon everyone and thank you for joining us on today's call.</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The third quarter 2020 results, we reported today, represent yet another record level of quarterly sales and a return to the levels of growth that are more representative of the demand for our EVO Visian ICL family of lenses. For the third quarter of 2020, STAAR'S net sales increased 21% over the prior year driven by 25% global ICL unit growth as markets more fully reopened following COVID-19 related shutdowns. On a regional basis, ICL unit growth in the third quarter was positive in a large majority of the top markets we track, as compared to the second quarter of 2020 when just three of our top markets achieved positive ICL unit growth, both metrics on a year-over-year basis. </p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Standout markets for ICL unit growth in the third quarter of 2020 compared to prior year included China up 33%, Japan up 67%, South Korea up 21%, Rest of Asia-Pacific up 67%, Spain up 24%, European distributor markets up 17% and Germany up 13%. India and the Middle East were the two markets that remained most challenged by COVID-19 during the third quarter with each market down more than 50% in ICL units over the prior-year period. Excluding India and the Middle East, global ICL unit growth for the third quarter of 2020 would have been 32% or 7 points higher than the 25% we reported. </p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Several factors contributed to our growth during the third quarter. </p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First, we benefited from our strong presence and growing share in Asia Pacific markets. Many APAC countries seem to be ahead of the curve with respect to effectively meeting and managing the COVID-19 challenge. Life appears to be returning to normal in Asia Pacific geographies earlier than many other locations around the globe. For example, our employees in Japan and China report that COVID-19 impacts daily life less than we're hearing from our employees in other parts of the world. Globally, we continue to support our customers in getting back to pre-COVID norms while also monitoring any developing trends or actions that could lead to business disruption. </p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second, we are observing an EVO patient in Asia and Europe that seems more motivated to reach a quick decision regarding refractive surgery, often selecting the first doctor he or she consults whereas historically these same patients may have met with two doctors or three doctors before making a final decision. The feedback we are receiving from clinicians is that patients are increasingly more motivated to quickly seek visual freedom as the pandemic has been quite challenging, as expressed by their patients who wear glasses and contact lenses. There also appears to be a sentiment amongst patients to do something good for themselves, as one of our clinicians in Spain shared with us.</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third, COVID-19 related closures and delays such as in the National College Entrance Exam in China, which was pushed back a month to July may have shifted some of our normal demand cycle from the second quarter into the third quarter. </font></p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And fourth, we effectively targeted and supported geographies with significant volume opportunity during the third quarter with patient recruiting, surgeon training and marketing. </p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the peak season in China, we resumed in-person or onsite patient educational roadshows at hospitals and hotels in the third quarter, where our customers promoted EVO with &#8220;high definition&#8221; and &#8220;premium&#8221; messaging. We had active marketing campaigns in China, Japan and Korea via digital, outdoor, commuter train, and subway stations and/or social media platforms. We also resumed advertising in Germany and Spain as those markets more fully reopened. </p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S., we expanded our strategic relationships with surgeons through a Refractive Restart program to support clinics as the U.S. market reopened. The success of this program has prompted a continuance of many facets of our surgeon support into and through the fourth quarter. </p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, as a measure of our success and awareness beyond just sales, our EVO websites drew twice as many unique visitors in the third quarter compared to the year-ago period. On a year-to-date basis, through the third quarter, our Doc Finder visits are up nearly 250% over the prior-year period. </p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Turning now to our pipeline of products, and potential key catalysts for STAAR in 2021, and beyond, we have made meaningful progress relating to our two new products for the U.S. and European markets. In the U.S., the primary study analysis cohort of 300 subjects has been enrolled and implanted with our EVO family of myopia lenses, which sets the stage for first-half 2021 submission to the FDA, and if marketing approval is obtained, the opening of the U.S. market to our EVO lenses. Our clinical trial sites continue to adhere to clinical trial protocols. We look forward to sharing additional details, when appropriate, in 2021. </p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Today, we also announced the initial launch and commercialization of our EVO Viva presbyopia-correcting lens in Europe. Details on our progress, including publication of the first peer-reviewed clinical paper, consumer websites launching in several countries and the first patient implant of the EVO Viva lens in Belgium are contained in a separate press release we issued this afternoon. </p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With Viva, STAAR has introduced an implantable lens to treat presbyopia designed to deliver all of the benefits of the EVO lens for myopia with the added benefit of addressing near intermediate and distance visual acuity. Clinical trial results have been evaluated and reported in an article written by our principal investigators and medical monitor and recently published in Clinical Ophthalmology. The conclusion of the study authors is as follows, "This multicenter prospective clinical investigation demonstrated the ability of the EDOF ICL to correct myopia and presbyopia resulting in improvement of uncorrected near, intermediate and distance visual acuity without compromising the quality of vision. The EDOF ICL allows subjects to perform tasks of daily living without glasses or contact lenses. Subjects reported significant improvements in quality of life with high levels of spectacle independence and satisfaction." </p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>We are conducting a phased rollout of our EVO Viva lenses to gather information on best practices in patient selection and patient management to optimize the objective and subjective factors that will delight patients in this large addressable market. The initial surgeons recognized as leaders in their respective markets for refractive surgery will be implanting the lens as well as making significant </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contributions to the EVO Viva playbook of best practices, thereby providing a pathway to full commercialization of the lens in the second half of 2021. </font></p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The third quarter of 2020 was a strong quarter for STAAR on multiple levels. Most importantly, we believe the essential fundamental demand for our EVO lenses has gained momentum, and is reflecting what we experienced pre-COVID. The STAAR team remains focused on creating a lens-based future within refractive vision correction where we believe we have the opportunity to move our global market share from 10% in the near-term to 20% to 30% plus global market share in the foreseeable future. </p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We feel very good about our business today and with the exception of the unknowns, which the pandemic holds, we are reiterating our outlook for the remainder of 2020, provided in August, which has us close-out the year with the fourth quarter in the range of approximately $43 million in net sales with the caveat of increased spending to support a strongly developing outlook for 2021. </p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patrick?</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Patrick F. Williams - Chief Financial Officer, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you Caren, and good afternoon everyone. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net sales for Q3 2020 were $47.1 million, up 21% as compared to the $39.1 million of net sales in the year ago quarter, and up 34% on a sequential basis from Q2 2020. The increase in net sales was attributable to the strong growth in those markets as Caren mentioned earlier. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In terms of product mix, ICL sales representative 88% of total company net sales for the third quarter 2020, and other products represented 12%, which is consistent with the recent trend. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross profit for Q3 2020 was $34.9 million or 74.1% of net sales as compared to gross profit of $29.1 million or 74.4% of net sales for the prior-year quarter and $24.4 million or 69.4% of net sales for Q2 2020. The 30 basis point change in gross margin as compared to prior-year quarter is primarily due to geographic sales mix, period costs associated with manufacturing expansion projects, and an increased sales mix of injector parts which carry a lower margin than our ICL. The 470 basis point sequential increase in gross margins from the second quarter is due to higher sales and a return to a more normalized level of manufacturing following a voluntary six-week COVID-19 manufacturing pause. Consistent with our comments on the last call, we continue to expect gross margin in the low 70% range for the fourth quarter of 2020. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>Moving down the income statement, total operating expenses for Q3 2020 were $30 million as compared to $25.7 million in the year-ago quarter and $25.5 million for Q2 2020. We continue our cost containment measures related to non-essential variable costs while also expanding programs designed to drive growth. We expect total Q4 2020 operating expenses to be similar to our Q3 2020 results. Taking a closer look at the components of operating expenses, G&amp;A expense for Q3 2020 was $8.6 million compared to $7.1 million for the year-ago quarter and $7.8 million for Q2 2020. The year-over-year increase in G&amp;A is due to increased salary-related expenses, variable compensation and facility costs. The increase from Q2 2020 was due to increased variable compensation, consulting costs and facility costs. For the fourth quarter, we expect G&amp;A to be up slightly from Q3 2020, as we begin investments to support 2021 and beyond. Selling and marketing expense was $12.7 million for Q3 2020 compared to $12.5 million for the year-ago quarter and $10.3 million for Q2 2020. The increase in selling and marketing expense from the prior-year quarter was due to increased salary related expenses, advertising and promotional activities, and variable </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compensation, offset by decreased tradeshow and travel expenses, and the increase from Q2 2020 was due to increased advertising and</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">promotional activities, salary-related expenses, variable compensation, and trade show expenses. For the fourth quarter, we expect selling and marketing expense to be down slightly from our Q3 2020 results. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense was $8.8 million in Q3 2020 compared to $6.2 million for the year-ago quarter and $7.3 million for Q2. The increase in research and development expense, as compared to both periods, was primarily due to increased clinical expenses associated with our EVO clinical trial in the U.S. and the increased salary-related expenses and variable compensation. For the fourth quarter, we expect R&amp;D to be up from our Q3 2020 results. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating income in Q3 2020 was $4.9 million or 10.4% of net sales as compared to $3.3 million or 8.5% of net sales for the year-ago quarter. The 190 basis point year-over-year expansion in operating margin is due to leverage on fixed and variable operating expenses during the quarter. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income for the third quarter was $4 million or $0.08 per diluted share compared to net income of $2.4 million or $0.05 per share in the year-ago quarter. On a non-GAAP basis, adjusted net income for Q3 2020 was $6.7 million or $0.14 per diluted share compared to adjusted net income of $5.5 million or $0.12 per diluted share in the year-ago period. A table reconciling the GAAP information to the non-GAAP information is included in today's financial release. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Turning to our balance sheet, our cash and cash equivalents, as of October 2, 2020, totaled $128.3 million, up $12 million compared to $116.3 million at the end of second quarter 2020. The sequential increase from the second quarter is primarily attributable to $9.6 million in cash generated from operations. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before we open up the call to your questions I would like to highlight several upcoming Investor meeting and conferences that STAAR will be attending. On November 17, STAAR will be attending the Jefferies London Virtual Healthcare Conference. On November 19, STAAR will be participating in the Stephens Annual Investment Conference. Caren and I look forward to speaking with many of you at these events in the coming weeks. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And this concludes our prepared remarks. Operator, we are now ready to take questions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Questions and Answers</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator:<font style="font-weight:bold;"> [Operator Instructions] </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And your first question comes from Anthony Petrone, Jefferies. Please go ahead, sir.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Anthony Petrone, Analyst, Jefferies LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oh, hi. Thank you. And hope everyone's doing well and congratulations on a good quarter here. I think Caren a couple on China first and then follow-up on EVO Viva. And just looking at the numbers for China, in particular, it actually looks like sequentially pricing sort of normalized and even improved. And so, maybe just to check our math there, did pricing in China improve? And when you look at the 33% implant increase, how does that stack up in terms of patients when you sort of bifurcate between high myopes and more moderate myope patients and then I'll have a follow-up on Viva. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Well, thank you, Anthony. Appreciate it. In terms of pricing in China, yes we had a strong quarter really on ASPs globally, and a lot of that was due to mix. And when we look at Toric versus spheric, our Toric business continues to improve as well as take a larger share of our total ICL volume. With regard to higher myop</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s versus medium myop</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s, we definitely, especially in China, which is specific to your question, we are definitely going down the diopter curve. We have stories of individuals at minus 1 that were very interested in not having any need for glasses, especially wearing masks as often as we do now. So yes, the mix in China is continuing to go down the diopter curve toward more of what has typically been a laser vision correction targeted market.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Anthony Petrone, Analyst, Jefferies LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Well, that's helpful, and then the two follow-ups real quick. I'll add one in there. One would be when you look at the China implant 33%, and Japan, in particular, up 67%, is there a way to splice out how much is still coming from deferred procedures coming back into the fold or is that new demand? And then, just the strategy for the launch with Viva, is that going to be a combination of direct and distributor. And I'll get back in queue. Thanks again.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. So with regard to our third quarter revenue, how much of it's new demand, how much of it is holdover, I did refer in my script in fact that there was some variation in normal &#8211; the normal busy season, for example, in China, in that young people, their college entrance exams were delayed, that made their going back to school delayed, which made third quarter heavier than for some categories, our most interested implant patients going up a bit in Q3. So, there was a little bit of that. But I believe, for the most part, when we talk to our clinicians, and surgeons, and what we get back is that there's just this tremendous interest and enthusiasm for visual freedom. And a lot of it is related to, I think, a reaction to the pandemic. And so, I would say that the majority of what we are seeing is not holdover but new demand. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to the Viva launch, as I said in my prepared remarks, we really are working with those refractive surgeons, in the major markets, across Europe, who are excellent at implanting our myopic EVO lens, and working with them on rolling out, very effectively, our new presbyopic lens, which adds several levels of new newness, so to speak, in terms of working with patients and understanding the motivation for which visual correction need they have the highest regard or highest requirement. So, as result of that, there's a lot of patient selection criteria that goes into it. You have to very properly target the patients. You need to make sure that you have excellent patient management post-surgery and follow-up. And so, with the best implanters we are rolling this product out, and we expect, by next year, hopefully in-person, in Barcelona, our EVO playbook will be made available and we will make the EVO Viva lens commercially available to all surgeons, including those who are currently served by our distributor, both those &#8211; our distributor markets both those that are our normal distribution as well as hybrid.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Anthony Petrone, Analyst, Jefferies LLCQ</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">That's great. Thanks, again.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You're welcome.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator: And your next question comes from Chris Cooley with Stephens.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Chris Cooley, Analyst, Stephens, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Good afternoon, everyone, and congratulations on the record quarter. Appreciate you taking the questions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thanks, Chris.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Chris Cooley Analyst, Stephens, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hey, thank you. If I could start with the U.S., maybe a little bit differently there, could you help us understand what the Refractive Restart program, Caren, what's the change in terms of your reach, when you think about the surgeon population here in the United States, if we think about the current kind of premium implanters for premium IOLs on the cataract side, but also higher end refractive practices. Just trying to think about what your current penetration is and how the Refractive Restart program has helped expand within that network kind of expectations there in advance of the launch next year? And I've got a quick follow-up.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sure. So, the Refractive Restart program was designed to support surgeons, who are coming back after the worst of COVID and reopening their practices, many of whom had been either strong to what I would call medium users of our Visian ICL in the U.S. The goal of the Refractive Restart was to help the surgeon attract patients by us providing the surgeon for bilateral implant patients, one of those lenses free of charge. And so, the surgeon had the opportunity there to determine how they wanted to offer that benefit to their patients.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">What we have found is that, a majority of the Refractive Restart surgeons that signed on, and there were hundreds, their goal was to really become more familiar with the Visian ICL in preparation for EVO and also to be able to offer their patients quite an opportunity to get our lenses versus potentially a LASIK procedure at maybe equal or even less price. <br /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And so, it got a lot of patients that maybe had in the past been told that either they did not qualify for a laser vision procedure. They were called again, and brought back in, and/or new patients who came in, who wanted visual freedom, and were offered EVO and whom, many of whom selected it. So, as a result of that, we were up sequentially over 70% in units, when you count those that were provided free of charge. So, we've had a lot of very happy patients, and a lot of very happy surgeons, who are getting more and more excited about the possibility of EVO coming to the U.S. next year.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Chris Cooley, Analyst, Stephens, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">That's great. I appreciate the color. And then, just lastly for me on the regulatory front, just want to make sure, we're level-set appropriately going into next year. Do you anticipate that you will require a panel for the EVO lens in the United States and also could you remind us expectations for when you might begin a trial or start the process for what I'm assuming there would be a supplemental filing for Viva here in the United States as well. Thank you and, again, congratulations on the quarter.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason</font><font style="font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Chris. As a Class III medical device, going for approval, we're on a panel track. It is our assessment that based on the fact that this is a safety study, where the endpoints are clear, at this point, we do not expect that there will be a panel but, of course, that is a decision for the FDA, but our belief, at this point, is that if and when we are able to provide the FDA with the critical information and data that supports approval that we would then be able to go direct to, to approval. With regard to bringing Viva to the United States, as soon as the full EVO family of lenses is approved by the FDA in the U.S., we are immediately going into an IDE discussion on bringing Viva to the U.S.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Chris Cooley, Analyst, Stephens, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Operator:<font style="font-weight:normal;"> Our next question comes from the line of Ryan Zimmerman, BTIG.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Ryan Zimmerman, Analyst, BTIG LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you. Congrats on the quarter. It's starting to see, a couple questions for me, number one, Caren, just love to &#8211; Japan is doing great. It's almost half the size now of China in terms of sales. And so, my previous viewpoint of that market was it was certainly a lot smaller than China. So, I'm just wondering if you could help us understand what your penetration looks like in Japan and whether your view of that market has changed, or has it gotten bigger, as Japan has outperformed just from a unit growth perspective?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.<font style="font-weight:normal;"><br />Well Japan is a very exciting story for STAAR. We have been working very effectively with the key opinion leaders in Japan, who are very significant in terms of the Japanese society's determination. And so what's been going on is that with the pullback of laser vision correction procedures, which at one point were above 400,000, now full refractive procedures in Japan are anywhere, per those surgeons, somewhere in the 80,000 to 100,000 procedure range. What we are now experiencing is above 30% at least market share. So, where we are headed in Japan is to continue to work with surgeon groups and practices and university KOLs who want to bring only lens-based practices as a standard to the market. And just recently, actually in August, Forbes Japan covered two of our surgeons, Dr. Shimizu and Dr. Kitazawa, and they themselves in that article, very clearly indicated what I just told you about laser vision correction, what's going on in terms of number of refractor procedures, and why the ICL is the best choice.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Patrick F. Williams, Chief Financial Officer, STAAR Surgical Co.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hey, Ryan, it's Patrick. And as a reminder......Japan, if you're looking at it, it does have our injector revenue in there. So that might be why you're kind of thinking that overall Japan is going higher. But just remember that so a couple million dollars a quarter of revenue that does get lumped into geography, Japan.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Ryan Zimmerman, Analyst, BTIG LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>Okay. That's very helpful. Thank you for that clarification, Patrick. And then, maybe just a follow-up, on Anthony's question, just actually, two quick ones from me. Just on the China performance, I mean certainly the data points have been very positive for the quarter. And Caren, I'm just wondering if you could speak a little bit to the seasonality, I guess, into the fourth quarter and your durability of that dynamic in the fourth quarter? I think certainly with some pull-forward or the dynamic of the college </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entrance </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exams</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I'm just wondering if you could kind of &#8211; if you're able to quantify what that benefit was and what you expect going forward in China?</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Well, we talked about in August what our growth projections were and what was being reported in terms of actual number of ICLs implanted and we came up with around 35% average. What we reported for the third quarter was 33% growth, that&#8217;s sales to the distributor. What has been going on, in a very strong China market for us, is demand outweighing what we are selling. And so, as a result of that, that's a good position to be in, in that we expect continuing growth even into the fourth quarter, and that we have used up quite a bit of the inventory in Q3, but all of that is figured into our projection of approximately $43 million in revenue for Q4 even with the very strong China and that's because we are looking at a global map of COVID and potential challenges with the additional, so the Middle East and India continuing to be on a slow recovery. But there is no doubt that China growth is very strong.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Ryan Zimmerman, Analyst, BTIG LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. That's very helpful. And then just quickly from me and I'll hop back in queue. You talked about timing with submission to the FDA, I think, first half 2021. Are you still expecting a few months potentially of being on the market in 2021, as you start to launch EVO in the U.S. or are you expecting &#8211; or at the very least, are you expecting some revenue at the tail-end of 2021 with EVO in the U.S. Thanks for taking the questions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sure. Thank you, Ryan. Well we would love to have EVO revenue in the U.S. the minute we can get it. So, at this point in time, we are uncomfortable and I'm sure you can imagine 100% saying that we expect to have revenue because we've got to get through the, and appropriately, with the FDA all the steps to approval. But I can tell you that everything is being prepared as if we could go to market tomorrow.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Ryan Zimmerman, Analyst, BTIG LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. Appreciate it. Congrats again</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Operator:<font style="font-weight:normal;"> Our next question comes from Andrew Brackmann with William Blair. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Andrew Brackmann, Analyst, William Blair &amp; Co. LLCQ</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hi, Caren. Hi, Patrick. Good afternoon and thanks for taking the questions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Caren, maybe to go back to a point you made earlier on the call related to patients making the ICL decision a little bit quicker than normal, I guess, how should we be thinking about that trend continuing over the longer-term? And, I guess, related to the demographic here, are there any other sort of macro changes that you've witnessed in this recovery period here?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>Yes. We have a weekly call with global representatives about markets and momentum and COVID and other obvious business indicators of where we're headed. And one of the things that keeps happening is that because of the necessary sacrifices that so many people are making, where they are unable to have the kind of social life, family events, et cetera, and because when they do go out, they have to wear </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">masks or other apparatus that are challenging for eyeglass, and contact lens wearers, there is this sentiment that they want to do something good for themselves, and we've heard that more than once. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We've heard it many times. And so you, I know, are aware that the plastic surgery experience right now is much greater. We believe that whether you're talking about aligners or our EVO lenses or certain procedures for aesthetic benefit, patients are just excited, and they're anxious, and once they make up their mind, they want it today. And so, people are going into our surgeons' offices, around the world, and going "I want EVO. I want it now. How fast can I have it?" And so that's a sea change from a couple of years ago where patients were, on average, surgeons would tell us patients would wait a year from the time they started researching and having one, two, or three visits with several doctors before they let anybody touch their eye. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Now, we think part of the reason why this has improved as well as social media has really picked up, and I talked about the fact that our Doc Finder visits are up 250% and, you know, when we're talking about events we do in China, hundreds of thousands of individuals, you know key in or listen to TikTok presentations et cetera. So, I just think the momentum is really out there for individuals who really want to take care of things that are challenging to them, and vision care is a really high priority.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Andrew Brackmann, Analyst, William Blair &amp; Co. LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Perfect. Thanks for all that color. Maybe shifting gears here just around market share, I think you had talked about 20% share in China sort of by year-end. So I guess, first, is that sort of the assumption that you're working with. And I guess longer-term... ...I think it was around this time last year you had sort of talked about the 25% target by the end of 2022. Obviously made some big strides this year, so, I guess, how should we be, thinking about that longer-term target, over the next couple of years?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk55469900"></a>Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes. We still are there. I mean if we could do the 25% earlier we will. The momentum is certainly, the winds at our back, and it's really up to us to make sure that we take excellent advantage, and do what we need to do, to make sure that we can deliver to China, all of the lens demand that we foresee. And yes, it is in the 25% range. We're already past 20%.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Andrew Brackmann, Analyst, William Blair &amp; Co. LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Perfect. Thanks, Caren. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Andrew. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Operator: <font style="font-weight:normal;">And your last question comes from Bruce Jackson, Benchmark. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Bruce D. Jackson, Analyst, The Benchmark Co. LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you for taking my question. If we could look at the seasonality in Europe in the fourth quarter generally, it's up sequentially. This year, we've got COVID-19, so the possibility of some increased lockdown and the offset of the EDOF launch. Earlier, you mentioned that the EDOF launch was going to be kind of a controlled launch. How are you looking at all these puts and takes in terms of the sequential sales growth for Europe in the fourth quarter?</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sure. Just as a reminder Bruce, last year, we switched from our normal sequential growth quarter-by-quarter through Q4, and Q3 became our largest quarter. And it is really based now on China being a big part of our units and, as a result of that, their busy season is an overwhelming indicator for growth in the Q2-Q3 timeframe. Q4, we then usually have Europe jump in, in a big way, and then Korea in the winter months that even blend into January et cetera. So, the way we see it is Q3 will be our biggest quarter this year, and Q4 will be very nice growth, double-digit growth, from prior year, but will be modulated a bit by our watching what's going on in certain markets around the world. Some not still fully recovered and others requiring shutdown. So, we just want to be careful and prudent and we measure this daily. And right now, what I'm reporting is what we see for the fourth quarter.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Bruce D. Jackson, Analyst, The Benchmark Co. LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. That's helpful. Thank you very much.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Bruce. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you for your participation on our call today. We look forward to speaking with many of you in the days and weeks ahead. We appreciate your interest and investment in STAAR Surgical. Please take good care, all the best to all of you. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Operator:<font style="font-weight:normal;"> Thank you for joining today's conference call. You may now disconnect.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">###</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>staa-20201104.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-11-05T14:59:46.5378426+00:00 -->
<!-- Version            : 5.0.1.513 -->
<!-- Package ID         : 19f603d00a14401e81da3bc6ac88d593 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:staa="http://www.staar.com/20201104" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.staar.com/20201104" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" namespace="http://fasb.org/srt/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd" namespace="http://fasb.org/srt-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" namespace="http://fasb.org/srt-types/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" namespace="http://fasb.org/us-gaap/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" namespace="http://fasb.org/us-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" namespace="http://fasb.org/us-types/2019-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.staar.com/20201104/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="staa-20201104_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="staa-20201104_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>staa-20201104_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-11-05T14:59:46.5378426+00:00 -->
<!-- Version            : 5.0.1.513 -->
<!-- Package ID         : 19f603d00a14401e81da3bc6ac88d593 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of each class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol(s)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of each exchange on which registered</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>staa-20201104_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-11-05T14:59:46.5378426+00:00 -->
<!-- Version            : 5.0.1.513 -->
<!-- Package ID         : 19f603d00a14401e81da3bc6ac88d593 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.staar.com/20201104/role/TemplateLink" xlink:href="staa-20201104.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="staa-20201104.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>staa-8k_20201104_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="staa-20201104.xsd" xlink:type="simple"/>
    <context id="C_0000718937_20201104_20201104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000718937</identifier>
        </entity>
        <period>
            <startDate>2020-11-04</startDate>
            <endDate>2020-11-04</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0000718937_20201104_20201104" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0000718937_20201104_20201104" id="F_000004">0000718937</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000718937_20201104_20201104" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000718937_20201104_20201104" id="F_000002">2020-11-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0000718937_20201104_20201104" id="F_000003">STAAR Surgical Co</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000718937_20201104_20201104" id="F_000007">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000718937_20201104_20201104" id="F_000006">0-11634</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000718937_20201104_20201104" id="F_000008">95-3797439</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000718937_20201104_20201104" id="F_000009">25651 Atlantic Ocean Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0000718937_20201104_20201104" id="F_000010">Lake Forest</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000718937_20201104_20201104" id="F_000011">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000718937_20201104_20201104" id="F_000012">92630</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000718937_20201104_20201104" id="F_000013">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000718937_20201104_20201104" id="F_000014">303-7902</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0000718937_20201104_20201104" id="F_000015">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000718937_20201104_20201104" id="F_000016">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000718937_20201104_20201104" id="F_000017">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000718937_20201104_20201104" id="F_000018">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0000718937_20201104_20201104" id="F_000019">Common</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000718937_20201104_20201104" id="F_000020">STAA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000718937_20201104_20201104" id="F_000021">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000718937_20201104_20201104" id="F_000005">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140427520805048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 04, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  04,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">STAAR Surgical Co<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000718937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-11634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3797439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">25651 Atlantic Ocean Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lake Forest<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">303-7902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">STAA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( '&&95$'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !QAF51@871&.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L,P#(9?9?B>R$YH#R;-I:.G#@8K;.QF;+4UBQ-C:R1]^SE>FS*V!]C1TN]/
MGT"-]E(/ 9_#X#&0Q?@PN:Z/4OL-.Q-Y"1#U&9V*94KTJ7D<@E.4GN$$7ND/
M=4*H.%^#0U)&D8(96/B%R-K&:*D#*AK"%6_T@O>?H<LPHP$[=-A3!%$*8.T\
MT5^FKH$[8(81!A>_"V@68J[^B<T=8-?D%.V2&L>Q'.N<2SL(>'O:O^1U"]M'
M4KW&]"M:21>/&W:;_%IO'P\[UE:\XH40!5\=Q%JNA*S%^^SZP^\N[ 9CC_8?
M&]\$VP9^W47[!5!+ P04    " !QAF51F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M '&&95%<-"GY. 0  #X0   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9AM<^(V$,=?7S^%AE?M3!(_\!1N"#,.25KF<@D-M#?33E\(>\&:V!(GB9!\
M^ZX,L;G4K)EI7@3+:/_^:7>]*S'<*OUL4@#+7O-,FJM6:NWZL^>9.(6<FPNU
M!HG?+)7.N<6A7GEFK8$GA5&>>:'O][R<"]D:#8M[4ST:JHW-A(2I9F:3YUR_
M74.FME>MH/5^XTFL4NMN>*/AFJ]@!O:/]53CR"M5$I&#-$))IF%YU8J"S]=A
MQQD4,_X4L#4'U\PM9:'4LQM,DJN6[X@@@]@Z"8X?+S"&+'-*R/%]+]HJG^D,
M#Z_?U>^*Q>-B%MS 6&7?1&+3J]9EBR6PY)O,/JGM;[!?4-?IQ2HSQ7^VW<WM
M=%HLWABK\KTQ$N1"[C[YZ]X1!P9A_XA!N#<("^[=@PK*&V[Y:*C5EFDW&]7<
M1;'4PAKAA'11F5F-WPJTLZ,;%6_0R99%,F&WT@K[QB9R%VWTVM"S^! WU8OW
M@M<[P?"(X(-ZN6!^YXR%?NC_:.XA6PD8EH!AH=<^HC=6+Z#9W]'"6(TA_(>0
M;)>2[4*RT[3F^=L:ZE9(FU^>?R$@.B5$AU2)D" I*.XROJJCH.V7/#- <'1+
MCNYISIB"%LKE0,(PDVK]0BL5D>^<_?3I4T/H>R5:CQ3<I^,3K(0+/C(^\+P6
MC-:9S:/HB<TV>B5BGK&Q(MCZ)5O_%+8Q>DZCYD0F\,J^P%L=':WDXU\_N!RT
M^P3698EU>0K6;0ZX6+EBOZ*]37')^9K+6CA:KRG+!B77X!2N.Y$!>]CD"]!U
M++2&?QX$O7:'H G\JNKYI_!,9*ST6NFBUIVQF<7$9TJCOS885PRO2FKSK4']
MYI:"/"C-P2F0<_[*)@DFFEAB_A:][+@+&R0'W?-V?]#OM <4856;@_ 4PBA)
M-!AS]G[![G$>>Y3UOJ,EPVZO&[#(9OB^BY@]QL EN]'8NBGBJO0'=/'^2#QV
M(XSX7&WKFQTM=\^?@>'V (RE\*JF$-!5_2->F9%3K5Z$C.L]2FN.(PJMZA,!
M7=X_HDV5L5CY_A+KXZ\)K3@(>VVJ3P15HPCH"E]$,<)=Z7$46J 7]BB0JBL$
M=#&_5Z[#3%,EJ3K7(-+VV^?]@1]21%5#".@*_DT+:T&Z%I!OY+Z F%JJ_]<*
M@JH7!'0AGZE,Q,*Z_O05TUL+GM7RT"I-/&'5#$*Z7$\UG,?H'L#W:[<OQ*T9
M;CH?E\OZ^#7H-9)5'2"DR_5_R";&;)"L$9"6;00\V)S3U7HN+'9TM63 XY3%
M&3>UJ=6@XG+SXUGC1Z"JOH=T09YKGKC$FKWE"Y7];'ZIQ:$UW'Z1@JFJ>4A7
M7K==+9T#KW'*Y0IO2+9-!=[1Q<86-"2UD W:T>PF^KT.TSLX#;J3]5?N]H*&
M9;!$)?^BCU59[PZKNX%5Z^* N% 6CYO%98H'?-!N GZ_5,J^#]R9L_S)8/0O
M4$L#!!0    ( '&&95&#J:4#U $  #(&   -    >&PO<W1Y;&5S+GAM;-55
MVXK40!#]E:8_P)Y$=D%) BHL""H+.P^^=I)*TM W.Y4QV:^W.YW;N RH#Z(O
MDSJGJD^=OD[6XR3AJ0- ,BJI^YQVB/8M8WW5@>+]*V-!^TQCG.+HH6M9;QWP
MN@^#E&3IZ73/%!>:%ID>U(/"GE1FT)C3$V5%UAB],Z]I)'PI5T N7.;T Y>B
M=&*NY4K(*=)I("HCC2/HK4!.D\#TSS&=1!1<+CI*:.,"R6*'^%LNY3\E5M1[
M**3<#*8T$D5F.2(X_>#!7#R3+U)DB<^3]0Y;QZ<DO:/[@/GCFY3&U>"V-@E=
MJ2*3T 0[3K1=^**Q+"01C?)!+7AK-)\]K".6P,M6(.53V,*OS97VV)"X%Q_K
ML TD3'4-O:$EC#(1!/VC6M0^R-[]D2RQXF+P_>!GHV?\;3 (CPX:,<YX;+;^
MM]23V^K<6CF]DZ+5"N+<?[EAD?%U'.F,$\^^6S@IE2? 47(!AZ(Z,M\=MV<8
M<3U-8W/;<_H?>OZ[Z]R"!L?ET;0_^O_R*O^.8[;<GL,5O;J@&TO"0YC3+^%]
ME;L'4@Y"HM +ZD1=@WYQ3[T\\M(_X%?ZOKZ&A@\2SULRIWO\&6HQJ#=;U6-8
MEZ5JCS^%]RBYGQON_Q+%#U!+ P04    " !QAF51EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( '&&95$ZJJ+G0 $
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( '&&95%<-"GY. 0  #X0   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !QAF51@ZFE ]0!   R!@  #0              @ %[#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( '&&95&7BKL<P    !,"   +
M  "  7H.  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( '&&95$ZJJ+G0 $  #P"
M   /              "  6,/  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" !QAF51)!Z;HJT   #X 0  &@              @ '0$   >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !QAF5199!YDAD!  #/ P
M$P              @ &U$0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"  #_$@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="staa-8k_20201104.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="staa-8k_20201104.htm">staa-8k_20201104.htm</File>
    <File>staa-20201104.xsd</File>
    <File>staa-20201104_lab.xml</File>
    <File>staa-20201104_pre.xml</File>
    <File>staa-ex991_15.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "staa-8k_20201104.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "staa-8k_20201104.htm"
     ]
    },
    "labelLink": {
     "local": [
      "staa-20201104_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "staa-20201104_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "staa-20201104.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "staa",
   "nsuri": "http://www.staar.com/20201104",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "staa-8k_20201104.htm",
      "contextRef": "C_0000718937_20201104_20201104",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "staa-8k_20201104.htm",
      "contextRef": "C_0000718937_20201104_20201104",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol(s)"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20201104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001564590-20-051424-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-20-051424-xbrl.zip
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M@UB4EQ!'.N?3.>>S90?RX=-L3, SX@(S>M'PFUX#(!JP$-/A16,J'"@"C!M
M1)"&D#"*+AIS)!J?/O[\TX=?' =<W73OP&40X6=TA45 F)AR]+;W^1WX^OOC
M+;C%]'L?"@2N6# =(QH!!XRB:-)VW9>7EV8XP%0P,HTDNV@&;.P"Q\F@.QQ!
M]0MP!2,$XJ\V./*./,?W'>_TR3]IG[;:)V?-T^/?SD^.SG[UO+;G+0'\E2P+
M+'VUP6G3:_K-4_]X:> ##+[#(0+=JZ6!?FMPYAV'G@?]DQ//1^=^"(_[P1D,
MSL_#T];R_ Z;S#D>CB+P-G@7ERC72RDB!,W!#::0!A@2T,M6^AYT:= $EX2
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M&.:3'5]7%;PE0=:JS(J4L$514D],$W%4GW(@#R-&:SZF7Y^WG8BK..:C&3.
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MT'\09/G K7RE_N5/>@@G_P;GX_]02P,$%     @ <89E44.+@"+V!   TRL
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M8"G=Y!*XYVQ3TVO9A#.E9563W]E62NKDE@ R5CF>*R>RSZ\5U+5F?1H <;N
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M"],[JWY;*B$KO"1T$_.X89VKL1;<T%HIZ':URK8I=E;4MJ!]-X:^+9+Z3#C
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M>PT#2/-'FBR=,&-KL\4EMDX6KVK<N<R"@S]^ZWT!MF>%++6,SA_MY-),]O-
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M&S<.//)E1YQ_*M)GPZM>;&1B/A<2Q.#7*F=.!D##P2</BZA'HE!W@DJJ4>&
M,^>]'IPNU&=3C9,WMB@N)4"'$^=3WMN/[EA, X,CIZ<>?."9[^V.#ZX^]/B4
MFW?.+HC"#>K!QF,2PD@N$T:<D*N I"BNXNPC=H/F #H472"<]6T(G-W?!LYN
M;N#L.BS].@3.8I;KIM.&C(\)O+K^VM,X)'/GP-BN^%]0>*/+7_D$NP_F]VO\
MXIH@4UT7(+"KN.<?D\LC?UH9ZJSH\/SS'R(RWRTX1)"R<CH4I1N5J'\#N*_/
MW K)-B2J-8<UBUI6#-2.1Y%F2*K 1J7CF_'^!^N9ZRK'96VC?L^\+N'Z,.R.
MN!<0/S,;7!(]SP@)>T&'7_=%^'CP6KYTWN>B7^)55RJ[0U4EOE<?<GU>L\9Y
MU&N<[[H=VVOQ<:[%:3#!U%J.J)YOQ)K/C]3H=6_;NGE\$%$]_>+1^,$5'K[U
M2R.78^_QT$&U9H_UWC) =839>X]-D)L%9WG/N+'%-'^K6;F!.#=8MU%%YY\N
MA]H2VE6$]G,/";PY-"#4%E/.5[OCW4<,%9SE12<H:Y+)V5-;A#3,_N7QI1$>
M1&##5SAKM (K8/1J]=4F..-+[HAO(CM5WKAW_SUSWC0N)A\[BW2H_0U#K2_"
M%W-]2DCBN(>.PA)OK\;'+F!3A]J$A"ORMYNYM:T4^J6FT>(;_ 6= 2Z(DU:M
M8I-,U[L6J:?3PN^Q_ZCGQQP;IH\V.]#V]KZ)6+=Z[ #YCQSSH>._]YQLBA^\
M(US0ZRKKH>"O'D>./6"!8ZDS6UDI*Q!EP ,C;W6 3])<B"'$B43:>6AXA7R/
MJ(_=I19S"/Q(6KJOJ^H61%6"NB>MT0;(8WWO#4UMEV09GTIN4!V3<54]\>30
M[V[OX>BJ!WFR4?]9(C@BH%_SFGM9_&!-T<Y3;MD5WKPV]N/UL;DE(,IR?"4*
M7N&;P2:'58613X*S<S"RY"I@I2>7RPP!B>#+1!02;<H)-0'87IMQY+YM'V\D
M@E];BO_(\""^$XQVEMJ$K4]THCT;0Z(BBHR)R66<9]JB4U;?XO$ZGL^?>N/G
M3*W[)7 6W)G#JEG:NKF9[<2_A.7FZB>7/6_Q^=WY[LK.HYM]3#=@Z8?2ZDYK
MTL,-3+AKD6@*EUJ5!PDQ3EY)-2ZISHR@.4J:O%Z_O#>$Y#[G3;VUW=]/YR-2
M8Z)^I&1+,;;0PH9\5K*!,B>R6!N&D>B8T:WJ?+M73H[D;%BO[J)B84QJ (H;
MSKUB@++SA?3;%!!3H6'UL55]PQ \X4MQ9$(,3N);>JEZ[OO?P"Y5A"&N1H0"
M0U-#D6RK?;U0I4H_;D1UZ_5V5!/7I.Z@1$]Q):),'4P,2HFO3,UD+HT; 9&,
ME"7!$7=).K?I.8M1,B7G4B T(M,U"Z-[$"0_U%]Y),97@ X4YPD<'-P-]??>
MK*!#(N'+[<@$U[,%3!IM5![G+O:8D3JL7],DGW9URN JMEVB8)O+:%&'K)Y+
MQ;?,V.*0+R(T3'] )U\3 7#EB1D>EAS4EH^\[[H-6V^,/G7GC9L3%W^P1=R\
MUK'Q&R#*/CAE[IOK :_YFY46Q*'9BRH9)&069(UQH(HDF& C]?GI0WDR2E:V
MD7K [')!)2T9(HX8].&;5[ZBC\'!.$NU<(KP@@+'/NQ>YF_'O7A:VB"=SH#@
MC-JXIFO(H"<IEZ?BI)-O0H6<3^_C5"B5>'%5/!N/VN'#^Z=#(XY66Q((\"2J
MCAC7?::.!,VVA8BZ)N%W>TWFT?BC 2Q(5VZW:,,6L3-#H2XM;@(#/H@FN(Y*
MFS<,+\+@_NO.P. 4Z<<B!7B0@IOE;L$0>.A.H$"9 )  #KIM))<]RR_RK&-$
M3]2<5'1X>WH?D8G+9:B,]&(;Q=-!-UH:QT/E5]9*;;.BK@P6M%2L_Y+Q6MA;
M#OP=25O,D%.['"=O'%B(H)(AQ[[75,,]5@?]S%VQ./J2W7RL1-*ZN&(:E:CM
M:J&0[XP2A!O?*&#?L,(Y -,J>,?'%T*W5*&\M89ID(XMF9_:K7346R*M]M_I
M>TRRL!-4_K$8*B;+$NTTV8H]>EI9=>&3\;;1^ I&&IM?W(X([V3DVDOFI>\X
MQ.T#&($_40R(9E$ *A,%V##<RD[929L+-D1H0D#LP]8U(PJXU&:<]:[?,Q)V
M *RFA6:(C/I6!0!8%&@#,26Q*R/?V,IZ(-=5"#@KBMVRQRGS(PG;\OT"Z.43
MV@)?RYZQW1$ IK2!DJ@'O,DS)/_)3!/N_ZF^!.(WP%;8^I:NA4UX R[\Z;E9
ML31:#O4]5@H'V1(U?#*=^D3X:D&6@D_TEV+]2U [8!>03(-6J?#-U+A[H-MR
ME:#I_8+[J*"V*O'MEFO)C6.X>9YRZX$0>-H,C[VW]ZWF%/!'I 2O%/I[Q+<O
M]/3I]0NI3FO!?5"H8AU_WVH+7$',MQXQ'[]O1!]@L'V!$(6^@$Q-^9'<8=]I
MITGGSA7]TZ+.Z./Q3LXM:1*^3=&4 ;5+1#^)<["2(LH]=S.+M1#ECL$_)&\G
M;F@26)&<1H6C'$5;2+(_;]O"\A-J=(R39\0@3SRLR2@P*WXC..THV"!D%9Q[
M<NB[D'AT<$'WDG]YO):>,S71>1*5*)/$QS6*HS+7-6%]XO0CJ4JVC&E*GM*P
MNXLPOV ]"6WUE4HC[_4<<1V@2>.\$P\!TCL2?4RY@>#060Z:'OKE0-ELK&7C
MKQ$U4.F92"Z6!S?5#_<% #M[+H-=%_@[EI.<6W)"AY)GRB V]AY7^QI'LW1U
M']Z6*OYUU#BF4(UN\PG[.G]Z6\JUEX(/.^*F/Q@4L#+H%-1"/8F0YOA6 C4R
M#7A&2OO#6=@2MC^0_A1K920F1=030JZXP#4K%&6J PK;("VJ"?D-/? B?D'_
M50Q;V[@0XA\-7-*#^0S\R1T\,T"L#'D,VEW))PS+V_7J1:8"6SST_*J'0&*7
M0-/ZXT0GJO )*81\R5MA2*;13%K/@T:!+80;?1G/D(0#+2DW7F%BS BX-FC4
M?Y &*3-QLKE 2^9&LF+4Z+V7I<OCL@0TCSQGTK!!&LA(_;%O %%<$&_<\2B$
M@FRE*G#/5 )8 $.7>1CLN@F00TH1'F2?(0^8/)B(?%KR"&4=%=TI3K@;<51(
M>B*$]A5\W,],31-VD&P^I3K@I_F\$I8^YL+D!2<]Z7OX6]Z&RS##/80:KECX
M)9((BV)PHSQFLEP[?WG(-*T%,!9-TZ2Y%J87Z;':R%5^YV7YVC,!C"-Z-/3]
MC?O/^)]HV:SW=<U7Q,VRK1[\L4S97VZ>K#D3*W8&'#AO'HVV]M'6/OHCVT""
MXVO.5"R0ZG%#Z>8+I0DE(6N&I=FFI)GG\YIDX7.RFZR 9H>DQR^_U3<RHOO-
M-J)[:R.ZGY]C;-]XP]_X636&B)=':J1GZ*/DI$IOH ;P_0!N<A3R\T97Y>0I
M7)R+.UU&N06P-UM)RI?"ORN2N;<4MM5)KS1LV)3A"[<EFS_$F&X/7_H!7+;M
M$XA/ILD)4GWAU>:6D,$=)>W=)'=V$!#(\BE7$;72'1[9LS( ^\1LL0"H=>\R
M%*<X1KRZ >7((_4NQ?KFFJ( ?A@\E&P5P$T_'_418<E:%NAOCJ9J.\F%6RA_
MY03G@!2 !)",SI&X*AQ24PY8K(VA[JB$^&TFF5S<4C7VSL'MZ3\^.?TI\'"T
MZL,J$_"8$;O[&>M,4Z$L-T<*^Q Z%8R3'SG24:\TP!M/::D>QSI,#'TXVSJ4
MPDJ+V>5[=IG3/'!  H7@0=%]@(M&A LX+%K\BBJA6K^')KOPO3RC4'5P//Y5
MH\T ;G, $N<@?^3WW#*>K;SZH&UXPYT*-##Y+JKF;,@(-M##N?5>Y^!ECI(U
M6#?CH8GH&XXE,&RGMB_S/1\E9!LU%/'5D#1FR8F<TE,M9YA@3>FD2?"5]?%"
M+E'51+^N ??0!,I?\X96S1F4,9 )ZI5GSH1.<AL6CT4CP1+L-N9ZJ%8&]PGQ
MF\D*[+AO?Q(_#!XVR1$,1;QH/50\XH0<G@+\Z-J( X%5?$CLF0;IPQCQN-B6
M2^TN?,/+S(*?H^FI<JP5+:92Y$@'T2+LR/?"DX ?#L''96XF"_G,(5.-1'.,
M:NHZZ90B030SB%E?06!1 VG4L,CM"L!3VN2$_M^<AJYMUOB4"*9;I4X-N4XL
M0T=(FV[L0AZWN!C> 0G=]I%%A)DX ;J0N"64$8TL>5J):0/BAGOLK;=:07 /
M-TZI6)-O0Y==1*V2GP[?G/RM3^[B-$]6?RRZVR%4R05&A66LZ!Q5U$\G=7+O
M!N;?^UN;MRJFA^'4QB>M8/6XS<J=%H E9H;7(L6-'U+6QQ<9F3K(=N!N@%-)
M:%M+) W;RVQN)40$!HD:KEEH(C_AAM(A76WDN\AS\+NOG7+H76_Y ?Q#&<DP
M!\0'2CG?%9IK%J@*3'R-I4L@&9DS?13:7(I#+Y7Z@3<:%ZAQBL=#:=H#VFLB
M197[N,9!21XAM(=99ZQX]])"D9)R 3TA#EO/S6*QBACUH$0@>N*R"*1[(#A$
MN(RAF,R^35DK[C7@A6N:O.^.R<A;(CTU 8,%55#[;BA/WCJZ/G*\](1;$JG/
M2I A"I^"&F6] MZ\$/90VM[[-8/!YFK&&X2ZR\_B3@\2,/A:U-IK; > EE'7
MZY#:SSD?/7TF1TX +"I%S(CR.#BQ0;-/N#U<98N0WA:Z]FZR'WO1U%O L F1
M,],,#2A)DU%64#(0B8 1&T6R0T8?2UX![24NV?A?097\N@0D7E>J#E='R=&&
M5=[":A.UJ4 JX:><H'&E]>LS'Z**XH33,94/7^&E].[)+W[E;V2H[>$VU';[
M0FV?4XY\<.GDPZM*)[^<,^/*RK+/.:71U5# G[57V\=QZWSL</'G[M'F Q+)
M(?3LYZB,2TY.3D)7^<Q>T%Z,5*JS00%I?V$*KP<PH(4(;?@^4%'$:=XP][C.
MKI&&UNQ4,-KGD\MTHNJ!7#K,)XV96E)YN??\2)MY*KP<PWPVXD@J.,?2_Y*_
M&85"O38TJH@J$SP<F,YT@@1.:/LTR\9JD0#/("/MJ8DQ>U\<'8H?F4'WD'X_
MO?1JGS:?3]6ND41\S-6;RVIH^"&CII!UWO)6Q_B*7$1D6LVB59=:$_;>&S"J
MA'"95V2:H_I0BI&08X\L4/W=I0KA"8H><;*LJGC;8NBCYZ(.2=3D8T//7JAE
M0K'<<EZL^MQ/4!)(_4HCUUHH!<U+$-@EA1&.B*-CY(>F7=/X+NH;YTBC?7$-
MZ-H+J]MK]&@ ;4L"'YS8=Z6X#8\FI^_*^N-P4RXNZ=<KNJG_C4M,/R53Y=G9
MR??;0N0/QIA?V[UP+[&--[,$.<+$>BYFZR5[E=2"KQNQL7V[8XM\'(]TU6.'
MBE]BI*!5":?M:(!:L:VDA,17(7#%,6-ZLR3QOA"\SA1<'\=MXSE$0CO X(R(
M-TG]<A3@9MSQ"+B*2YDN<M2\7>1V*4#C'@5$:AW8UY[+'Z0SHB]7L5)G8%/"
MKZHE@_PV<2O"F2"^%0?#@:7?U/LH29Q?%<3G$'0<>HYPNF@9L@VJ?[!3F'^
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M"CAOI7H+.2T?@J*$2!ETIV.(0;(4D70]BJB7,Q\S]KII\#N2JU%5=5SF\#5
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M-"YX<V102P$"% ,4    " !QAF51Z*;*4"0'  ":20  %0
M@ '>!   <W1A82TR,#(P,3$P-%]L86(N>&UL4$L! A0#%     @ <89E44.+
M@"+V!   TRL  !4              ( !-0P  '-T86$M,C R,#$Q,#1?<')E
M+GAM;%!+ 0(4 Q0    ( '&&95')<-S$6A8  )7/   4              "
M 5X1  !S=&%A+3AK7S(P,C Q,3 T+FAT;5!+ 0(4 Q0    ( '&&95%&D^G8
MU#<  .@U 0 1              "  >HG  !S=&%A+65X.3DQ7S$U+FAT;5!+
4!08     !0 % $8!  #M7P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
